$ 184.83 <%= Resources.Global.txtDown %>
Updated 23/06/2019
Change % -1.22% Stock price decreasing
Change -2.28 Stock price decreasing
Volume 2,300,874
High $ 187.00
Low $ 184.70
Open $ 186.54
ISIN
Prev close $ 187.11
# of shares 609.94M
Market cap 112,734M USD
Intraday

Market closed
Amgen Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  184.83 1.8% Stock price increasing 7.9% Stock price increasing -0.9% Stock price decreasing 3.6% Stock price increasing -0.3% Stock price decreasing
Powered by TradingView

News about Amgen Inc

  • English
  • Regulatory news

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Abbott Laboratories 84.71 1.5% Stock price increasing 10.0% Stock price increasing 8.3% Stock price increasing 29.2% Stock price increasing 39.4% Stock price increasing 17.1% Stock price increasing
 
Bristol-Myers Squibb Company 45.68 -4.4% Stock price decreasing -2.4% Stock price decreasing -3.8% Stock price decreasing -6.3% Stock price decreasing -16.4% Stock price decreasing -12.1% Stock price decreasing
 
Johnson & Johnson 143.06 2.0% Stock price increasing 3.0% Stock price increasing 4.7% Stock price increasing 16.5% Stock price increasing 16.7% Stock price increasing 10.9% Stock price increasing
 
Eli Lilly and Company 115.63 0.9% Stock price increasing -1.0% Stock price decreasing -11.0% Stock price decreasing 8.3% Stock price increasing 34.8% Stock price increasing -0.1% Stock price decreasing
 
Merck & Company Inc (new) 85.51 1.2% Stock price increasing 5.3% Stock price increasing 3.8% Stock price increasing 20.2% Stock price increasing 39.1% Stock price increasing 11.9% Stock price increasing
 
Pfizer Inc 43.76 1.6% Stock price increasing 4.3% Stock price increasing 4.5% Stock price increasing 7.9% Stock price increasing 20.3% Stock price increasing 0.3% Stock price increasing
 
Merck Kgaa O.N. 92.90 -0.9% Stock price decreasing 2.5% Stock price increasing -5.9% Stock price decreasing -0.5% Stock price decreasing 13.5% Stock price increasing 3.2% Stock price increasing
 
Novartis NAM SF 0,50 81.43 -0.3% Stock price decreasing 5.0% Stock price increasing -0.9% Stock price decreasing 10.3% Stock price increasing 28.4% Stock price increasing 9.4% Stock price increasing
 
Roche Hldg AG GEN 245.80 -1.5% Stock price decreasing 2.1% Stock price increasing 2.4% Stock price increasing 15.8% Stock price increasing 31.7% Stock price increasing 14.1% Stock price increasing
 
Glaxosmithkline PLC ORD 25P 1,593.00 -0.1% Stock price decreasing 0.7% Stock price increasing 2.8% Stock price increasing 6.4% Stock price increasing 6.1% Stock price increasing 6.8% Stock price increasing
 
Takeda PHARM.CO.LTD. 30.30 -0.7% Stock price decreasing -4.6% Stock price decreasing -17.7% Stock price decreasing 2.1% Stock price increasing -13.2% Stock price decreasing 4.7% Stock price increasing
 
Sanofi 77.12 -0.5% Stock price decreasing 2.6% Stock price increasing -1.1% Stock price decreasing 3.9% Stock price increasing 11.4% Stock price increasing 1.9% Stock price increasing
 
Biogen Inc 235.91 1.2% Stock price increasing 3.9% Stock price increasing 7.1% Stock price increasing -15.3% Stock price decreasing -19.3% Stock price decreasing -21.6% Stock price decreasing
 
Bayer AG NA O.N. 55.34 2.3% Stock price increasing 2.7% Stock price increasing -3.9% Stock price decreasing -9.9% Stock price decreasing -42.5% Stock price decreasing -8.6% Stock price decreasing
 
Teva Pharmaceutical Industries.. 8.250 -1.3% Stock price decreasing -24.1% Stock price decreasing -48.1% Stock price decreasing -43.5% Stock price decreasing -65.0% Stock price decreasing -46.5% Stock price decreasing

Company profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Peers

Instruments Last Change  
Abbott Labor.. 84.71 -0.3% Stock price decreasing
Bristol-Myer.. 45.68 -7.4% Stock price decreasing
Johnson & Jo.. 143.06 0.7% Stock price increasing
Eli Lilly an.. 115.63 0.1% Stock price increasing
Merck & Comp.. 85.51 1.1% Stock price increasing
Pfizer Inc 43.76 0.2% Stock price increasing
Merck Kgaa O.. 92.90 1.3% Stock price increasing
Novartis NAM.. 81.43 0.0% Stock price unchanged
Roche Hldg A.. 245.80 -1.7% Stock price decreasing
Glaxosmithkl.. 1,593.00 1.1% Stock price increasing
Takeda PHARM.. 30.30 -0.8% Stock price decreasing
0,0,100,100,100,0,0,0,0,0
Sanofi 77.12 -0.7% Stock price decreasing
Biogen Inc 235.91 -1.3% Stock price decreasing
Bayer AG NA .. 55.34 0.9% Stock price increasing
Teva Pharmac.. 8.250 -2.4% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2019 03:28:40
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-25 04:28:40 - 2019-06-25 03:28:40 - 1000 - Website: OKAY